Cited by 247Extracellular vesicles in diseaseGlioma Diagnosis and TreatmentMicroRNA in disease regulation

Glioblastoma: exosome and microRNA as novel diagnosis biomarkers

Saadatpour, L, Fadaee, E, Fadaei, S, Nassiri Mansour, R, Mohammadi, M, Mousavi, S M, Goodarzi, M, Verdi, J +1 more·2016·Cancer Gene Therapy

Abstract

Glioblastoma (GBM) is known as a tumor type, which arises from astrocytes. Several studies indicated that GBM tumor cells are malignant. This is because of the fact that they consist of different cell types, which are reproducing very quickly and are also supported by a large network of blood vessels. The correct identification of various stages of GBM could help to better treat the patients with this disease. Therefore, new biomarkers such as exosomes and microRNAs (miRNAs) may help us to learn more about GBM and they may also lead to a more effective treatment for patients with GBM. Exosomes have emerged as biological vehicles, which can perform various tasks in carcinogenesis pathways such as PI3K/AKT, SOX2, PTEN, ERK, and STAT3. The miRNAs are known as small noncoding RNAs that are involved in several GBM pathogenic events. These molecules have key roles in various biological processes such as angiogenesis, metastasis and tumor growth. In this study, we highlighted various exosomes and miRNAs that could be used for diagnosis and/or prognosis biomarkers in patients with GBM.

Integrity signals

Registry

Crossref · 10.1038/cgt.2016.48

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Saadatpour, L., Fadaee, E., Fadaei, S., Nassiri Mansour, R., Mohammadi, M., Mousavi, S. M., Goodarzi, M., Verdi, J., & Mirzaei, H.
Affiliations
  • Isfahan University of Medical Sciences (IR)
  • Islamic Azad University of Najafabad (IR)
  • Kashan University of Medical Sciences (IR)
  • Lorestan University of Medical Sciences (IR)
  • Tehran University of Medical Sciences (IR)
  • KU Leuven (BE)
  • Mashhad University of Medical Sciences (IR)
Corresponding author
Mirzaei, H
Venue
Cancer Gene Therapy
Published
2016-11-11
Volume
23
Issue
12
Pages
415-418
ISSN
  • 0929-1903 (ISSN-L)
  • 1476-5500
OpenAlex
W2552834147
Cited by
244
References
78
Citations by year
2026: 7 · 2025: 9 · 2024: 14 · 2023: 19 · 2022: 30 · 2021: 39 · 2020: 34 · 2019: 24 · 2018: 32 · 2017: 34 · 2016: 2
FWCI
2.78
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Gene Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
glioblastoma, exosomes, microRNA, diagnostic biomarkers, prognostic factors, tumor microenvironment, angiogenesis, metastasis, PI3K/Akt signaling, SOX2, PTEN, ERK, STAT3, carcinogenesis
MeSH terms
Animals, Glioblastoma, Humans, Prognosis, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, MicroRNAs, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review